109.55
price up icon0.23%   0.25
 
loading
Schlusskurs vom Vortag:
$109.30
Offen:
$108.69
24-Stunden-Volumen:
3.23M
Relative Volume:
0.90
Marktkapitalisierung:
$19.95B
Einnahmen:
$381.03M
Nettoeinkommen (Verlust:
$-1.01B
KGV:
-18.41
EPS:
-5.95
Netto-Cashflow:
$-789.25M
1W Leistung:
+0.79%
1M Leistung:
+13.95%
6M Leistung:
+37.02%
1J Leistung:
+52.56%
1-Tages-Spanne:
Value
$107.07
$109.88
1-Wochen-Bereich:
Value
$106.54
$113.10
52-Wochen-Spanne:
Value
$60.40
$113.10

Insmed Inc Stock (INSM) Company Profile

Name
Firmenname
Insmed Inc
Name
Telefon
908-977-9900
Name
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Name
Mitarbeiter
1,271
Name
Twitter
@insmed
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
INSM's Discussions on Twitter

Vergleichen Sie INSM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INSM
Insmed Inc
109.55 21.13B 381.03M -1.01B -789.25M -5.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
366.54 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.00 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
438.93 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
661.83 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
288.18 35.49B 3.81B -644.79M -669.77M -6.24

Insmed Inc Stock (INSM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-13 Eingeleitet Jefferies Buy
2025-02-25 Eingeleitet RBC Capital Mkts Outperform
2024-04-23 Eingeleitet Truist Buy
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2023-11-20 Fortgesetzt JP Morgan Overweight
2023-07-26 Eingeleitet Guggenheim Buy
2022-12-09 Eingeleitet Mizuho Buy
2022-12-07 Eingeleitet Barclays Overweight
2022-11-18 Eingeleitet BofA Securities Buy
2022-04-27 Eingeleitet Goldman Buy
2021-12-06 Eingeleitet JP Morgan Overweight
2021-10-19 Fortgesetzt Monness Crespi & Hardt Buy
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-10-08 Eingeleitet Cantor Fitzgerald Overweight
2021-04-26 Fortgesetzt Credit Suisse Outperform
2020-12-17 Eingeleitet Berenberg Buy
2020-10-12 Fortgesetzt Stifel Buy
2019-09-03 Eingeleitet Goldman Buy
2019-04-09 Bestätigt H.C. Wainwright Buy
2019-02-15 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-01-17 Hochstufung Goldman Neutral → Buy
2019-01-02 Eingeleitet Canaccord Genuity Buy
2018-08-06 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2018-07-23 Eingeleitet Goldman Neutral
2018-04-23 Hochstufung Credit Suisse Neutral → Outperform
2018-03-21 Eingeleitet Morgan Stanley Overweight
2018-01-18 Eingeleitet Credit Suisse Neutral
2017-09-05 Bestätigt Evercore ISI Outperform
2017-08-17 Eingeleitet Evercore ISI Outperform
2017-07-11 Eingeleitet Robert W. Baird Outperform
2016-03-15 Eingeleitet Stifel Buy
2015-11-09 Herabstufung UBS Buy → Neutral
2015-10-06 Bestätigt H.C. Wainwright Buy
2015-06-09 Eingeleitet Citigroup Neutral
2014-03-26 Bestätigt HC Wainwright Buy
Alle ansehen

Insmed Inc Aktie (INSM) Neueste Nachrichten

pulisher
Aug 09, 2025

Insmed Incorporated (NASDAQ:INSM) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 09, 2025

Real time scanner hits for Insmed Incorporated explainedBollinger Band Squeeze and Expansion Analysis - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

H.C. Wainwright Maintains Buy Rating on Insmed with $120 Price Target - AInvest

Aug 09, 2025
pulisher
Aug 08, 2025

Insmed's $350M Trade Ranks 273rd as High-Volume Strategy Generates 166% Alpha - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed's Q2 net loss reaches $322M, but shares surge 68% amidst revenue guidance and Russell index inclusion. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed (INSM) Reports Increased Losses But Reiterates 2025 Revenue Guidance - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed stock price target raised to $120 from $108 at RBC Capital - Investing.com Australia

Aug 08, 2025
pulisher
Aug 08, 2025

UBS Adjusts Price Target on Insmed to $133 From $124, Maintains Buy Rating - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Raises Price Target on Insmed to $120 From $108, Keeps Outperform Rating - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed: Q2 Earnings Snapshot - Connecticut Post

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed Reports Q2 Earnings with 19% ARIKAYCE Revenue Growth and Positive TPIP Study Results - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed Inc (INSM) Q2 2025 Earnings Call Highlights: Strong Finan - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

Insmed Reports Strong Growth and Strategic Advances - TipRanks

Aug 08, 2025
pulisher
Aug 08, 2025

Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus

Aug 08, 2025
pulisher
Aug 07, 2025

Insmed Sets $405M-$425M ARIKAYCE Revenue Target as Brensocatib Launch Approaches and Pipeline Advances - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed's Q2 2025: Key Contradictions in Bronchiectasis Strategy, Pricing, and Market Access - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed stock price target raised to $129 by Jefferies ahead of PDUFA - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Affirms 2025 Global Arikayce Revenue Target of $405M-$425M, Below Consensus Estimate of $466.61M - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Q2 2025 Earnings Call Transcript - MarketBeat

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Insmed Q2 2025 sees revenue beat, stock dips - Investing.com Australia

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update - Insmed Incorporated Investor Relations

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Q2 2025 slides reveal 19% revenue growth amid clinical pipeline advances - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Inc. shares fall 1.53% premarket despite Q2 revenue beating estimates. - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Reiterates ARIKAYCE Revenue Guidance for 2025 - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Q2 Earnings: $321.7M Loss, Misses Analyst ForecastsNews and Statistics - IndexBox

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Inc (INSM) Surpasses Q2 2025 Revenue Estimates with $107. - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed earnings missed by $0.40, revenue topped estimates - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Q2 Loss Narrows, Revenue Rises - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update | INSM Stock News - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed Q2 Revenue Up 19%, Exceeds Expectations - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

FEAM releases new Fort Cady PFS, advancing boron project plans | INSM SEC FilingForm 10-Q - Stock Titan

Aug 07, 2025
pulisher
Aug 07, 2025

Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - Eastern Progress

Aug 07, 2025
pulisher
Aug 06, 2025

INSMED Inc Executives Make Significant Stock Purchases and Sales - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

JPMorgan Chase & Co. Increases Stake in Insmed Inc. - GuruFocus

Aug 06, 2025
pulisher
Aug 05, 2025

Insmed INSM Q2 2025 Earnings Preview Upside Potential on Promised Revenue Growth - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance

Aug 05, 2025
pulisher
Aug 04, 2025

Insmed Surges 2 35 on Pipeline Breakthroughs and Capital Restructuring Despite Ranking 449th in Daily Liquidity - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

October 17th Options Now Available For Insmed (INSM) - Nasdaq

Aug 04, 2025
pulisher
Aug 04, 2025

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - The Globe and Mail

Aug 04, 2025
pulisher
Aug 04, 2025

Price Floor Holding on Insmed Incorporated — Rebound PossibleTop Performing Stock Insights Released Daily - metal.it

Aug 04, 2025
pulisher
Aug 03, 2025

Should I hold or sell Insmed Incorporated stock in 2025Discover high-return stocks for your portfolio - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Insmed Incorporated stock compared to the marketUnlock powerful stock screening tools today - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Insmed Incorporated stock overvalued or undervaluedFree Popular Stock Recommendations - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Insmed Incorporated stockExceptional financial outcomes - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Insmed Incorporated Stock Analysis and ForecastInvest confidently with real-time market updates - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Insmed Incorporated generate profit in a changing economyStay informed with expert market forecasts - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Insmed Incorporated compare to its industry peersCapitalize on momentum-driven investment opportunities - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is Insmed Incorporated company’s growth strategyRemarkably fast returns - Jammu Links News

Aug 03, 2025

Finanzdaten der Insmed Inc-Aktie (INSM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Insmed Inc-Aktie (INSM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lewis William
Chair and CEO
Aug 04 '25
Sale
109.81
6,830
750,008
233,924
Flammer Martina M.D.
Chief Medical Officer
Aug 04 '25
Option Exercise
19.74
8,715
172,034
91,826
Flammer Martina M.D.
Chief Medical Officer
Aug 04 '25
Sale
109.50
8,715
954,292
83,111
$28.66
price up icon 2.10%
$37.58
price up icon 1.54%
$78.39
price up icon 0.24%
$111.66
price up icon 0.28%
biotechnology ONC
$288.18
price down icon 3.39%
Kapitalisierung:     |  Volumen (24h):